Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31646425 | 0.78 | — | — | |
| SCHEMBL705951 | 0.77 | GRIN2B (0.33) | GRIN2BGRIN2CUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL502555 | 0.77 | GRIN2B (0.33) | GRIN2BGRIN2CUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL15116517 | 0.77 | GRIN2B (0.33) | GRIN2BGRIN2CUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL6919845 | 0.77 | GRIN2B (0.33) | GRIN2BGRIN2CUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL31645901 | 0.76 | NR1H2 (0.34) | GRIN2BGRIN2CUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL15106078 | 0.75 | GRIN2B (0.32) | GRIN2BGRIN2CUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL15113974 | 0.75 | GRIN2B (0.34) | GRIN2BGRIN2CUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL22231289 | 0.74 | USP2 (0.39) | GRIN2BGRIN2CUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL3632957 | 0.73 | USP2 (0.41) | USP2SMN1; SMN2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133915-A1 | COMPOUNDS WHICH BIND TO PNPLA3I148M AND THEIR USE TO TREAT LIVER DISEASES | NOVARTIS AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |